Why Did Jon Medved's ALS Diagnosis Lead to a Shocking Resignation? The Unexpected Twist Will Leave You Speechless!

When venture investor Jon Medved began supporting health-care startups several years ago, he likely didn't foresee that these companies would one day adapt to his personal health challenges. In October, Medved, a prominent figure in Israel's venture capital landscape, announced his immediate retirement after being diagnosed with amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease.

“It happened quite suddenly,” he told TechCrunch in a hoarse voice—a symptom of ALS—during what could be his last interview.

ALS is a progressive neurodegenerative disease that affects motor neurons in the brain, leading to loss of muscle control, which severely impacts the ability to walk, speak, eat, and breathe. Understanding that the condition only worsens over time, Medved is committed to leveraging technology to remain connected with his loved ones and maintain a role in the innovative world he helped to establish.

Medved is often referred to as the “father” of Israel’s startup ecosystem, a title earned during his journey from California to Israel, where he founded and sold several successful companies. In 2013, he launched OurCrowd, a platform that revolutionized venture capital by allowing accredited investors to participate in funding opportunities traditionally reserved for larger institutions.

OurCrowd has since evolved into a global network, attracting around 240,000 accredited investors from 195 countries, including doctors and lawyers. The platform has backed notable companies like Anthropic, Beyond Meat, and Lemonade, and currently supports approximately 500 portfolio companies, boasting around 74 exits. One standout exit was LocusView, which was sold for $525 million to Itron.

Despite regional conflicts and ongoing humanitarian crises, Israel's startup ecosystem has shown remarkable resilience. As the so-called “Startup Nation,” Israel continues to play a pivotal role across various sectors, including cybersecurity, defense technologies, artificial intelligence, microchips, enterprise software, and medical technologies. In November, Medved noted an impressive influx of capital: approximately $800 million was invested in the Israeli venture ecosystem in just one week. Overall, the total annual venture investment in the country hovers around $15 to $16 billion.

Now, the technologies emerging from the startups that Medved has nurtured are helping him navigate the complexities of living with an incurable disease. An innovative digital avatar has been created, capturing his voice, facial expressions, and overall demeanor. This digital twin is a product of a collaboration involving D-ID, a company within OurCrowd’s portfolio, and voice AI startup ElevenLabs, with support from the Scott-Morgan Foundation, which focuses on ALS.

“These things have become very, very personal to me,” Medved shared.

Though stepping back from the company’s leadership, Medved is determined to continue contributing to both OurCrowd and the broader startup ecosystem. He asserts,

“I am far from done, okay? I want to continue making my contribution, to OurCrowd and to the broader ecosystem.”

Reflecting on his journey, Medved expressed pride in being part of a movement that transcends mere financial investment.

“I’m very proud that, even as investors, we are part of this movement.”

The story of Jon Medved serves as a powerful reminder that modern technology not only drives business value but also enables individuals to remain active participants in society, even amid personal adversity. As he adapts to his new reality, Medved exemplifies resilience and the potential for technology to bridge gaps in communication and connection, illustrating how innovation can impact lives in profound ways.